202 related articles for article (PubMed ID: 21707867)
41. Plasma sex steroid hormones and breast cancer risk in Chinese women.
Yu H; Shu XO; Shi R; Dai Q; Jin F; Gao YT; Li BD; Zheng W
Int J Cancer; 2003 May; 105(1):92-7. PubMed ID: 12672036
[TBL] [Abstract][Full Text] [Related]
42. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.
Dorgan JF; Stanczyk FZ; Longcope C; Stephenson HE; Chang L; Miller R; Franz C; Falk RT; Kahle L
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):177-81. PubMed ID: 9138660
[TBL] [Abstract][Full Text] [Related]
43. Androstenediol complements estrogenic bioactivity during the menopausal transition.
Lasley BL; Chen J; Stanczyk FZ; El Khoudary SR; Gee NA; Crawford S; McConnell DS
Menopause; 2012 Jun; 19(6):650-7. PubMed ID: 22415563
[TBL] [Abstract][Full Text] [Related]
44. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
45. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients.
Mady EA; Ramadan EE; Ossman AA
Dis Markers; 2000; 16(3-4):151-7. PubMed ID: 11381198
[TBL] [Abstract][Full Text] [Related]
46. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
Sikora MJ; Cordero KE; Larios JM; Johnson MD; Lippman ME; Rae JM
Breast Cancer Res Treat; 2009 May; 115(2):289-96. PubMed ID: 18521740
[TBL] [Abstract][Full Text] [Related]
47. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density.
Rannevik G; Jeppsson S; Johnell O; Bjerre B; Laurell-Borulf Y; Svanberg L
Maturitas; 1995 Feb; 21(2):103-13. PubMed ID: 7752947
[TBL] [Abstract][Full Text] [Related]
48. Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells.
Turgeon C; Gingras S; Carrière MC; Blais Y; Labrie F; Simard J
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):151-62. PubMed ID: 9699868
[TBL] [Abstract][Full Text] [Related]
49. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women.
Adly L; Hill D; Sherman ME; Sturgeon SR; Fears T; Mies C; Ziegler RG; Hoover RN; Schairer C
Int J Cancer; 2006 Nov; 119(10):2402-7. PubMed ID: 16894564
[TBL] [Abstract][Full Text] [Related]
50. Effects of CYP7B1-mediated catalysis on estrogen receptor activation.
Pettersson H; Lundqvist J; Norlin M
Biochim Biophys Acta; 2010 Sep; 1801(9):1090-7. PubMed ID: 20553962
[TBL] [Abstract][Full Text] [Related]
51. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Worgul TJ; Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
[TBL] [Abstract][Full Text] [Related]
52. A chromatography/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume.
Caron P; Turcotte V; Guillemette C
Steroids; 2015 Dec; 104():16-24. PubMed ID: 26254607
[TBL] [Abstract][Full Text] [Related]
53. Resveratrol Inhibits Key Steps of Steroid Metabolism in a Human Estrogen-Receptor Positive Breast Cancer Model: Impact on Cellular Proliferation.
Poschner S; Maier-Salamon A; Zehl M; Wackerlig J; Dobusch D; Meshcheryakova A; Mechtcheriakova D; Thalhammer T; Pachmann B; Jäger W
Front Pharmacol; 2018; 9():742. PubMed ID: 30042681
[TBL] [Abstract][Full Text] [Related]
54. Serum levels of 5-androstene-3 beta,17 beta-diol sulphate, 5 alpha-androstane-3 alpha, 17beta-diol sulphate and glucuronide, in late onset 21-hydroxylase deficiency.
Montalto J; Funder JW; Yong AB; Whorwood CB; Connelly JF
J Steroid Biochem Mol Biol; 1990 Nov; 37(4):593-8. PubMed ID: 2177625
[TBL] [Abstract][Full Text] [Related]
55. Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells.
Adams J; Garcia M; Rochefort H
Cancer Res; 1981 Nov; 41(11 Pt 1):4720-6. PubMed ID: 6458355
[TBL] [Abstract][Full Text] [Related]
56. Bioassays for estrogenic activity: development and validation of estrogen receptor (ERalpha/ERbeta) and breast cancer proliferation bioassays to measure serum estrogenic activity in clinical studies.
Li J; Lee L; Gong Y; Shen P; Wong SP; Wise SD; Yong EL
Assay Drug Dev Technol; 2009 Feb; 7(1):80-9. PubMed ID: 19382890
[TBL] [Abstract][Full Text] [Related]
57. Binding characteristics of [3H]delta(5)-androstene-3beta,17beta-diol to a nuclear protein in the rabbit vagina.
Traish AM; Huang YH; Min K; Kim NN; Munarriz R; Goldstein I
Steroids; 2004 Jan; 69(1):71-8. PubMed ID: 14715380
[TBL] [Abstract][Full Text] [Related]
58. Dehydroepiandrosterone and estrone 17-ketosteroid reductases in MCF-7 human breast cancer cells.
MacIndoe JH; Hinkhouse M; Woods G
Breast Cancer Res Treat; 1990 Oct; 16(3):261-72. PubMed ID: 1964814
[TBL] [Abstract][Full Text] [Related]
59. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Ingle JN; Kalari KR; Buzdar AU; Robson ME; Goetz MP; Desta Z; Barman P; Dudenkov TT; Northfelt DW; Perez EA; Flockhart DA; Williard CV; Wang L; Weinshilboum RM
Steroids; 2015 Jul; 99(Pt A):32-8. PubMed ID: 25163006
[TBL] [Abstract][Full Text] [Related]
60. Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer.
Kakugawa Y; Minami Y; Tateno H; Inoue H; Fujiya T
Breast Cancer; 2007; 14(3):269-76. PubMed ID: 17690503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
